- Home
- GUT vs UPB Comparison
GUT vs UPB Comparison
Compare GUT & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUT
- UPB
- Stock Information
- Founded
- GUT 1999
- UPB 2021
- Country
- GUT United States
- UPB United States
- Employees
- GUT N/A
- UPB N/A
- Industry
- GUT Trusts Except Educational Religious and Charitable
- UPB
- Sector
- GUT Finance
- UPB
- Exchange
- GUT Nasdaq
- UPB NYSE
- Market Cap
- GUT N/A
- UPB 521.3M
- IPO Year
- GUT N/A
- UPB 2024
- Fundamental
- Price
- GUT $5.27
- UPB $8.84
- Analyst Decision
- GUT
- UPB Strong Buy
- Analyst Count
- GUT 0
- UPB 4
- Target Price
- GUT N/A
- UPB $56.50
- AVG Volume (30 Days)
- GUT 176.3K
- UPB 327.1K
- Earning Date
- GUT 01-01-0001
- UPB 05-06-2025
- Dividend Yield
- GUT 10.93%
- UPB N/A
- EPS Growth
- GUT N/A
- UPB N/A
- EPS
- GUT N/A
- UPB N/A
- Revenue
- GUT N/A
- UPB $2,296,000.00
- Revenue This Year
- GUT N/A
- UPB N/A
- Revenue Next Year
- GUT N/A
- UPB $0.99
- P/E Ratio
- GUT N/A
- UPB N/A
- Revenue Growth
- GUT N/A
- UPB N/A
- 52 Week Low
- GUT $4.60
- UPB $5.14
- 52 Week High
- GUT $7.38
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- GUT 49.45
- UPB N/A
- Support Level
- GUT $5.20
- UPB N/A
- Resistance Level
- GUT $5.39
- UPB N/A
- Average True Range (ATR)
- GUT 0.06
- UPB 0.00
- MACD
- GUT 0.00
- UPB 0.00
- Stochastic Oscillator
- GUT 53.85
- UPB 0.00
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.